CD19 and acute lymphoblastic leukemia: Unlike B-ALL where nearly all cancer cells express the CD19 antigen, solid tumors are often comprised of tumor cells with diverse and heterogeneous expression levels of target antigen, rendering them insensitive to CAR T cell recognition (32).